Supplement Claims Need Healthy Support, Not A Disease Cohort
This article was originally published in The Tan Sheet
Executive Summary
Supplement firms should ensure supporting studies for structure/function claims avoid drug treatment findings, says NPA CEO Dan Fabricant. People with “higher-end-of-normal” range of health issues are critical to avoiding trial outcomes that attract FTC scrutiny.